---
figid: PMC6200414__nihms-989275-f0003
figtitle: Phospholipid-binding tumor suppressor ANXA7 linked to the interrelated FGF8
  and cyclin E pathways through Ca/phospholipid signaling in prostate cancer
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC6200414
filename: nihms-989275-f0003.jpg
figlink: /pmc/articles/PMC6200414/figure/F3/
number: F3
caption: Custom pathway of FGF-signaling with interrelated ANXA7, FGF8 and cyclin
  E links (all three highlighted in blue) was developed using the Ingenuity Pathways
  Analysis, IPA as described in ‘Materials and Methods’. Additional ANXA7 links are
  presented on a small image in the left corner. Overlay with gene expression profile
  (red – upregulated, green – downregulated) corresponds to the prostate cancer subtype.
papertitle: Cyclin E and FGF8 are downstream cell growth regulators in distinct tumor
  suppressor effects of ANXA7 in hormone-resistant cancer cells of breast versus prostate
  origin.
reftext: A Bera, et al. Trends Cancer Res. 2018;13:55-62.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.885105
figid_alias: PMC6200414__F3
figtype: Figure
redirect_from: /figures/PMC6200414__F3
ndex: c1181b52-df0e-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6200414__nihms-989275-f0003.html
  '@type': Dataset
  description: Custom pathway of FGF-signaling with interrelated ANXA7, FGF8 and cyclin
    E links (all three highlighted in blue) was developed using the Ingenuity Pathways
    Analysis, IPA as described in ‘Materials and Methods’. Additional ANXA7 links
    are presented on a small image in the left corner. Overlay with gene expression
    profile (red – upregulated, green – downregulated) corresponds to the prostate
    cancer subtype.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ELK1
  - KCNH4
  - KCNH8
  - CBL
  - FGF1
  - FGF13
  - FGF17
  - CP
  - IGF1
  - FGF7
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF12
  - FGF14
  - FGF16
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - GRP
  - LSM4
  - LGALSL
  - UCMA
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - SPR
  - TACR1
  - HGF
  - IL6
  - SOS1
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - GAB1
  - PIGU
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PTPN11
  - GRB2
  - XYLT2
  - SOS2
  - HRAS
  - BDKRB2
  - PLCG1
  - PLCG2
  - HSPG2
  - PLCE1
  - PLCZ1
  - PLCB1
  - PLCB2
  - PLCB3
  - PLCB4
  - PLCD1
  - PLCD3
  - PLCD4
  - PDGFRB
  - PDGFRA
  - SOST
  - FRS2
  - AKT1
  - AKT2
  - AKT3
  - MAP3K1
  - CRAT
  - MAP2K1
  - ITPR1
  - ANXA7
  - MAP2K3
  - MAP2K7
  - MAP2K2
  - STAT3
  - CRK
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - LGALS3
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - ETFA
  - MAPKAPK2
  - TP53
  - TP63
  - TP73
  - MTG1
  - PTEN
  - PDGFB
  - PDGFA
  - PDGFC
  - PDGFD
  - AR
  - SRI
  - PTK2B
  - EGFR
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - GDNF
  - GAST
  - SPRY1
  - SPRY2
  - SPRY3
  - SPRY4
  - CCNE1
  - RAC1
  - RNASE1
  - APC
  - JUP
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K6
  - EPHB2
  - APOA1
  - CYP1A1
  - Inositol Phosphate
  - 12(S)-hydroxyeicosatetraenoic acid
  - guanosine
  - Ga2
  - gemfibrozil
  - clofibrate
  - Ca2+
  - Cancer
  - Lung cancer
  - Noonan syndrome
---
